Live Markets
Saturday, September 12, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets

Aspire-Lakewood Holdings, Inc. (ASBPW)

NCM

$0.010.00 (0.00%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
P/E (TTM)
EPS
Div Yield
52W Range
$0.01–$0.01
Beta
0.17

Company overview

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.

Peers in industry

Aspire-Lakewood Holdings, Inc. has no peer companies in this window.

Recent press releases

April 2026

5 months agoS-1/A

Aspire Biopharma Holdings, Inc. — S-1/A Filing

ASBPWAspire Biopharma Holdings, Inc.

# 🧾 What This Document Is This is an **amended registration statement (S-1/A)**. Think of it as the final paperwork needed to let certain investors sell the shares they recently bought from the company. * **Why it exists:** Aspire Biopharma raised $11 million in February 2026 by selling special

Read summaryView on SEC EDGAR

March 2026

5 months ago10-K

Aspire Biopharma Holdings, Inc. — 10-K Filing

ASBPWAspire Biopharma Holdings, Inc.

# 🧾 What This Document Is This is Aspire Biopharma's **10-K annual report**, the comprehensive yearly filing required by the SEC for public companies. It’s a deep dive into their business operations, financial performance, and the risks they face. Think of it as the company's official report card f

Read summaryView on SEC EDGAR

SEC filings

All filings →
2 recent filings shown in the timeline above. View all SEC filings →

Aspire-Lakewood Holdings, Inc. has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
UBS Group AG$331,963
2,514,873 sh+32727.0%
688,143 sh+2252.1%
232,661 sh-50.8%
813,427 sh0.0%
428,552 sh0.0%
265,471 sh+853.2%
247,555 sh-1.0%
202,897 sh0.0%

People at Aspire-Lakewood Holdings, Inc.

All people →

No officers or directors have been indexed for Aspire-Lakewood Holdings, Inc..

Quarterly financials

Full financials →
Revenue trend
03/25
NI -$15.9M
06/25
NI -$2.0M
09/25
$1.9K
NI -$1.9M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $-0.04
Prior: $-0.04
Revenue sparkline